Generic Name and Formulations:
Lipase/protease/amylase: 3000Units/9500Units/15000Units; 6000Units/19000Units/30000Units; 12000Units/38000Units/60000Units; 24000Units/76000Units/120000Units; 36000Units/114000Units/180000Units; del-rel caps containing e-c spheres.
Indications for CREON:
Treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.
Adults and Children:
See literature. Start at the lowest recommended dose and increase gradually. Individualize based on clinical symptoms, the degree of steatorrhea present, and the fat content of the diet. Infants: May sprinkle directly into mouth or into a small amount of applesauce; do not mix directly into formula or breastmilk. ≤12months: 3000 lipase units per 120mL of formula or per breastfeeding. Children and adults: Do not crush or chew caps; swallow whole, or may open and sprinkle contents into small amount of acidic food (pH≤4) and swallow mixture immediately. >12months–<4yrs: 1000 lipase units/kg per meal; ≥4yrs: 500 lipase units/kg per meal. Max (for children and adults): 2500 lipase units/kg per meal (or ≤10000 lipase units/kg per day), or <4000 lipase units/g fat ingested per day. Adults with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy: individualize; in one study, patients received 72,000 lipase units per meal while consuming 100g of fat per day; lower starting doses are consistent with the 500 lipase units/kg per meal lowest starting dose recommended for adults in the guidelines.
Not interchangeable with any other pancrelipase products. Pork allergy. Potential viral transmission. Gout. Renal impairment. Hyperuricemia. Contents irritating to mucosa. Pregnancy (Cat.C). Nursing mothers.
Pancreatic enzymes (porcine).
Abdominal pain, abnormal feces, cough, dizziness, flatulence, headache, weight decreased; hyperuricemia, fibrosing colonopathy (with high doses), allergic reactions.
Caps 3000—70; 6000, 12000, 24000, 36000—100, 250
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|